Lakewood-Amedex Biotherapeutics Highlights Nu-3 Resistance Data in Response to National Action Plan of Presidential Advisory Council on Combating Antibiotic Resistant Bacteria
Rhea-AI Summary
Lakewood-Amedex Biotherapeutics (NASDAQ: LABT) highlighted new resistance data for its Phase 2-ready antimicrobial candidate Nu-3, being developed for infected diabetic foot ulcers (iDFU). Nu-3 targets and disrupts bacterial membranes via a unique, physical mechanism of action and has shown a high barrier to resistance.
According to Lakewood-Amedex Biotherapeutics, Nu-3 did not induce resistance in a serial passage experiment and demonstrated broad-spectrum in vitro activity against bacteria harboring diverse resistance mechanisms, including target modifications (e.g., vanA/vanB, mec, rpoB, PBP2x), β-lactamase variants (NDM, ESBL, AmpC, CRE), sul2-mediated metabolic resistance, and efflux pumps. The company positions its Bisphosphocin® platform as aligned with the U.S. National Action Plan on Combating Antibiotic-Resistant Bacteria discussed at the June 16, 2026 PACCARB meeting.
Positive
- Nu-3 showed no induced resistance in a serial passage experiment
- Broad-spectrum in vitro activity against multiple antibiotic resistance mechanisms, including β-lactamases and efflux pumps
- Phase 2-ready Nu-3 aligned with U.S. National Action Plan on antibiotic resistance
Negative
- None.
Market reaction after Nu-3 resistance data: LABT +83.33% in the Jul 22 session
In the Jul 22 session, LABT gained 83.33%, reflecting a significant positive market reaction. Argus tracked a peak move of +276.4% during that session. Argus tracked a trough of -10.1% from its starting point during tracking. Our momentum scanner triggered 169 alerts that day, indicating very high trading interest and price volatility. Trading volume was exceptionally heavy at 204.8x the daily average, suggesting very strong buying interest.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jul 15 | Preclinical safety data | Positive | -4.7% | Preclinical safety results supported dose selection for the upcoming Phase 2a iDFU trial |
| Jul 07 | Antimicrobial policy support | Positive | -12.8% | Company supported PASTEUR Act reintroduction and greater focus on antimicrobial-resistance incentives |
| Jun 25 | Clinical leadership appointment | Positive | -7.8% | David G. Armstrong was appointed study chair and scientific advisor for the Phase 2a iDFU program |
| Jun 22 | Patent grant | Positive | -7.2% | Australian composition-of-matter patent expanded protection for Bisphosphocin antimicrobial compounds |
| Jun 16 | Investor forum presentation | Neutral | -0.7% | Company scheduled a Life Sciences Virtual Investor Forum presentation covering its Nu-3 development program |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent company news was followed by negative 24-hour reactions, including after several positive developments, showing repeated divergence between announcement tone and observed price response.
Key Terms
serial passage experiment medical
efflux pump medical
β-lactamase medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Nu-3, a Phase 2-ready candidate targeting the treatment of infected diabetic foot ulcers (iDFU), targets disruption of bacterial membranes through a unique, physical mechanism of action and has demonstrated a high barrier to resistance.
The 27th Public Meeting of PACCARB convened on June 16, 2026, with discussion focused on the next 5-year iteration of the National Action Plan on Combating Antibiotic-Resistant Bacteria. The plan functions as a roadmap for the
"The rising tide of antimicrobial resistance represents one of the most severe, global crises in modern medicine, making the acceleration of novel therapeutic platforms a foremost priority," said Kelvin Cooper, Ph.D., CEO of Lakewood-Amedex Biotherapeutics. "We are answering this national call to action by advancing our proprietary Bisphosphocin® platform. Our lead candidate, Nu-3, directly aligns with the objectives outlined by PACCARB, by targeting and disrupting bacterial membranes through a unique, physical mechanism of action. Moreover, Nu-3 has demonstrated a high barrier to resistance, positioning it as a highly differentiated candidate with potential to help address these critical national goals, while providing a valuable option for the millions of patients impacted by iDFU."
Lakewood-Amedex Biotherapeutics recently announced that Nu-3 does not induce resistance in a serial passage experiment. In additional laboratory profiling, Nu-3 has demonstrated broad spectrum in vitro activity against bacteria with a diverse range of resistance mechanisms, including modifications to the target of the antibiotic, direct metabolism of the agent, and efflux pump mechanisms. Antibiotic target mutation resistance examples include vanA and vanB variants in E. faecalis and E. faecium, mec variants in H. influenzae, S. aureus, S. pneumoniae, rpoB variants in K. pneumoniae, and PBP2x variants in S. pneumoniae. Antibiotic metabolism resistance examples include the β-lactamase variants NDM, ESBL, AmpC, and CRE, in E. cloacae, E. coli, K. pneumoniae, P. aeruginosa, P. mirabilis, and C. freundii, as well as the metabolic pathway variant sul2 in A. baumannii. Efflux variant examples include metal-tetracycline/H+ antiporter in S. epidermis, and the benzalkonium chloride efflux pump in S. marascens.
By bypassing these widespread resistance mechanisms, Lakewood-Amedex Biotherapeutic's platform offers a promising therapeutic avenue that directly supports the federal mandate to bolster the pipeline of innovative, resistance-evading anti-infective therapies.
About Lakewood-Amedex Biotherapeutics Inc.
Lakewood-Amedex Biotherapeutics Inc. (NASDAQ: LABT) is a clinical-stage biotechnology Company developing a novel class of fast-acting, broad-spectrum antimicrobials – the Bisphosphocin® class - to treat infectious diseases and reduce the threat posed by antibiotic-resistant bacterial strains, including MRSA, VRE, and others. For more information, please visit https://lakewoodamedex.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding Lakewood-Amedex Biotherapeutics Inc.'s clinical development plans, regulatory strategy, anticipated trial timing, potential regulatory submissions or approvals, and the potential benefits, safety, efficacy and commercial potential of its Bisphosphocin® platform and product candidates. These statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially, including risks that clinical trials may not be initiated, completed or successful on expected timelines or at all; preclinical or clinical results may not be predictive of future results; product candidates may not demonstrate safety or efficacy or receive regulatory approval; and risks related to manufacturing, supply, financing and other matters described in the company's SEC filings, including under "Risk Factors." Forward-looking statements speak only as of the date of this press release, and the company undertakes no obligation to update them except as required by law.
Contact
Investor Relations
Tiberend Strategic Advisors, Inc.
David Irish
(231) 632-0002
dirish@tiberend.com
Media Relations
Tiberend Strategic Advisors, Inc.
Casey McDonald
(646) 577-8520
cmcdonald@tiberend.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/lakewood-amedex-biotherapeutics-highlights-nu-3-resistance-data-in-response-to-national-action-plan-of-presidential-advisory-council-on-combating-antibiotic-resistant-bacteria-302831490.html
SOURCE Lakewood-Amedex Biotherapeutics Inc.